Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2016 Q2- Text added to 2016 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
New words:
AACR, absence, acute, Anderson, Ascenta, biochemical, castrate, Center, checkpoint, DNA, expressing, fourth, hepatocellular, high, immune, immunotherapy, ipilimumab, liver, lymphoblastic, MD, member, nonclinical, overexpressing, overexpression, pharmacological, potent, prostate, radiation, reductase, toxicology, translational, vitro
Removed:
afatinib, AstraZeneca, attained, Auckland, Boehringer, Bristol, carcinoma, cardiac, conclusion, conventional, cycle, cyotoxic, dacomitinib, depending, dose, EGFR, electrical, Erbitux, head, heart, hypoxic, induced, Ingelheim, inhibitor, irreversible, kinase, lengthening, licensor, mediated, mice, mutant, neck, nivolumab, overcome, pembrolizumab, Pfizer, plasma, prematurely, progressing, prolongation, QT, recurrent, responsive, signaling, Squibb, suggest, TKI, toxicity, tyrosine, undergoing, usable, xenograft
Valuein 2016 Q2 filing- Value in 2016 Q3 filing
Original filings
Filing view